Clinical trials
Node-positive Breast Cancer clinical trials
Below are recruiting node-positive breast cancer clinical trials, each written for real people, not researchers. We’re tracking 18 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06999798RecruitingPhase 1
A better ultrasound marker for lymph nodes in breast cancer
This trial tests a new ultrasound marker to help surgeons find and remove cancer-positive lymph nodes during breast cancer surgery. The marker makes the node easier to see on ultrasound so it can be taken out accurately.
Rochester, MinnesotaAges 18 years+ - NCT06876714RecruitingPhase 3
Shorter vs Longer HER2 Therapy for Breast Cancer with Complete Response
This trial compares 6 months versus 12 months of HER2-targeted therapy for people with HER2+ breast cancer who had a complete response after chemo and trastuzumab. The goal is to see if a shorter treatment is just as effective.
Phoenix, ArizonaAges 18 years+ - NCT04665882Recruiting
Prediction tool for arm swelling after breast cancer surgery
This trial tests a prediction tool (a “nomogram”) to estimate who is at risk of developing breast cancer–related lymphedema, or long-term arm swelling, after surgery. If you fit the surgery and lymph node criteria, your information may help personalize follow-up and prevention.
Wuhan, HubeiAges 18–80 - NCT04886531RecruitingPhase 2
Pre-surgery neratinib plus hormone therapy with trastuzumab
This study tests whether a pre-surgery treatment plan that adds neratinib to hormone therapy and trastuzumab can shrink HER2-positive, ER-positive breast cancer before surgery. It may help patients by improving how much cancer is eliminated at the time of surgery.
Chicago, IllinoisAges 18 years+ - NCT05333328RecruitingPhase 4
Test of ovarian function suppression for low-risk premenopausal node+ breast cancer
This trial studies whether ovarian function suppression (a treatment that lowers hormone production from the ovaries) helps women with hormone-receptor positive, HER2-negative breast cancer that has spread to lymph nodes, but who have a low-risk result on a genomic test. It may help reduce breast cancer recurrence while avoiding more intensive treatment for those who are lower risk.
Seoul, KoreaAges 20–50 - NCT05427071Recruiting
Tracking a breast cancer marker to guide lymph node surgery
This study tests a special “marker” technique to help surgeons find affected lymph nodes in the armpit after chemotherapy. It may support more targeted surgery and help avoid unnecessary removal of healthy lymph nodes.
Hong KongAges 18 years+ - NCT05462457Recruiting
Tests adding a targeted approach for breast cancer with many involved nodes
This trial studies a treatment plan for early breast cancer that involves at least three suspicious lymph nodes on the ultrasound/imaging. It looks at whether a targeted technique—done before surgery with chemotherapy—can improve or guide care when surgery will remove the lymph nodes.
EssenAges 18 years+ - NCT05491226RecruitingPhase 2
Pembrolizumab plus radiation and myeloid-targeting for high-risk breast cancer
This trial studies whether adding pembrolizumab (an immune “unlocking” drug) to radiation and another treatment that targets certain immune cells can improve outcomes for women with high-risk, early-stage triple negative breast cancer. You may be considered if your cancer has signs that it may respond less to immunotherapy on its own.
Los Angeles, CaliforniaAges 18 years+ - NCT06171360Recruiting
Gut bacteria and CDK4/6 inhibitor treatment in breast cancer
This study looks at how gut bacteria affect response to a type of targeted therapy (CDK4/6 inhibitors) combined with hormone therapy in breast cancer that is hormone receptor-positive and HER2-negative. It may help find out why some people respond better to treatment and could lead to better personalized care.
BrusselsAges 18–100 - NCT06517212RecruitingPhase 2
Tirzepatide for weight loss in MRD-positive early breast cancer
This study tests whether the weight-loss drug tirzepatide (Mounjaro) can help prevent breast cancer from coming back in people who are overweight and have a sign of leftover cancer cells in their blood (called MRD-positive). You must have already finished at least one year of hormone therapy for early-stage breast cancer.
Dallas, TexasAges 18 years+ - NCT06559540RecruitingPhase 2
Compare short radiation courses for node-positive breast cancer
This study compares two shorter courses of radiation therapy for women with node-positive breast cancer. It aims to see if an ultra-short course is as safe and effective as the slightly longer short course.
St Louis, MissouriAges 18 years+ - NCT06833502RecruitingPhase 2
Screening for breast cancer spread after chemo and surgery
This trial aims to find out if doing special scans to check for breast cancer spread to organs (not just lymph nodes) is helpful in certain patients. The study looks at people with breast cancer that had already spread to lymph nodes and did not completely go away with chemotherapy and surgery.
Tampa, FloridaAges 18 years+ - NCT07076485RecruitingPhase 2
Shorter radiation after surgery for node-positive breast cancer
This trial tests shorter radiation schedules for people with breast cancer that has spread to lymph nodes or is high-risk. It aims to find a shorter course of radiation that is just as effective after surgery.
Loveland, ColoradoAges 18 years+ - NCT07140172Recruiting
Radiation or surgery for node-positive breast cancer
This trial compares two treatments for people with breast cancer that has spread to the lymph nodes: radiation therapy to the armpit or surgery to remove the lymph nodes. The goal is to see which approach works best after a tailored surgery to remove the most suspicious lymph nodes.
Bethesda, MarylandAges 18 years+ - NCT07276880RecruitingPhase 2
Chemo, immunotherapy, and radiation for lymph node-positive triple-negative breast cancer
This trial tests a combination of chemotherapy, the immunotherapy drug pembrolizumab, and low or high-dose radiation before surgery for people with triple-negative breast cancer that has spread to the lymph nodes. The goal is to see if this approach can improve treatment outcomes.
Chapel Hill, North CarolinaAges 18 years+ - NCT07622836Recruiting
Chemotherapy plus QL1706 for high-risk triple-negative breast cancer
This study tests whether adding a new immunotherapy drug called QL1706 to standard chemotherapy after surgery can help patients with aggressive triple-negative breast cancer that has spread to lymph nodes. The goal is to see if this combination prevents cancer from coming back.
Nanjing, JiangsuAges 18–75 - NCT06190639RecruitingPhase 2
Sintilimab after surgery for node-positive esophageal cancer
This trial tests whether giving the immunotherapy drug Sintilimab after surgery can help prevent esophageal cancer from coming back. It is for people whose cancer had spread to lymph nodes and who have already had their tumor removed.
Hangzhou, ZhejiangAges 18 years+ - NCT06671262RecruitingPhase 2
Immunotherapy plus radiation before breast cancer surgery
This trial tests combining two treatments—an immunotherapy drug (Toripalimab) and radiation—before surgery for a certain type of breast cancer (HR+, HER2-negative) that has spread to lymph nodes. The goal is to see if this combination helps shrink the tumor more than standard therapy alone.
Hangzhou, ZhejiangAges 18–85
Hear when a new Node-positive Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for node-positive breast cancer?
- Yes. Clin2 currently lists 18 recruiting node-positive breast cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a node-positive breast cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a node-positive breast cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Breast Cancer Early Stage Breast Cancer (Stage 1-3)
- Breast Cancer (Triple Negative Breast Cancer (TNBC))
- HER2-positive Breast Cancer
- Hormone-receptor-positive Breast Cancer
- ER Positive Breast Cancer
- Estrogen-receptor-positive Breast Cancer
- HER2-positive Metastatic Breast Cancer
- Hormone Receptor Positive HER-2 Negative Breast Cancer
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.